Methylation of p16 and p15 genes in multiple myeloma.
- Author:
Wenming CHEN
1
;
Yin WU
;
Jiazhi ZHU
;
Jingzhong LIU
;
Shuzhen TAN
;
Chengqing XIA
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; genetics; DNA Methylation; DNA, Neoplasm; genetics; Gene Silencing; Genes, p16; Humans; Multiple Myeloma; genetics; pathology; Prognosis; Transcription Factors; genetics; Tumor Suppressor Proteins
- From: Chinese Medical Sciences Journal 2002;17(2):101-105
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the frequency of p16 and p15 gene methylation in multiple myeloma (MM), and its relationship with bone marrow cell apoptosis and clinical outcome.
METHODSTwenty-two patients with MM were studied to detect p16 and p15 gene methylation. Methylation-specific polymerase chain reaction (MSP) was used to detect gene methylation, and terminal transferase-mediated dUTP nick end-labeling (TUNEL) was used to detect cell apoptosis.
RESULTSp16 and/or p15 gene methylatoin was detected in 10 of 22 patients (45.4%). There were 3 patients with p16 gene methylation, 9 patients with p15 gene methylation, and 2 patients with both genes methylation. The incidence of methylation of p15 gene was higher than that of p16 gene (P < 0.05). The patients with p16 and/or p15 gene methylation had a delayed cell apoptosis, poor response to chemotherapy, and a short over-all survival (OS).
CONCLUSIONThe methylation of p16 and/or p15 gene plays a key role in MM apoptosis pathogenesis. The patients with both p16 and p15 gene methylation had a poor prognosis.
